Real-Time Analysis of Cellular Phagocytosis; Characterization of Anti-CD47 Antibodies as Potential Novel Immuno-Therapies

Alongside intense efforts to exploit T-cells as immunotherapies for cancer (e.g. checkpoint inhibitors, CAR-T, T-cell metabolism), researchers are increasingly considering other immune cell types for novel targets. One example is the enhancement of macrophage function via inhibitors of CD47 “don’t-eat-me” signaling proteins, enabling tumor cells to evade clearance by neighbouring phagocytes (Kim et al, 2012, Leukemia 26, 2538–2545). In order to identify new CD47 and phagocyte modulators, novel, direct and validated assays with throughput commensurate to drug discovery are required.
Watch this webinar to learn how:

•Real-time live-cell analysis using pH-sensitive fluorescent probe-labeled target cells can be used to visualize and quantify phagocytosis. •You can share data on the pro-phagocytic effects of anti-CD47 antibodies. •Other live-cell phenotypic assays (e.g. apoptosis, proliferation) are used to validate mechanisms of action.